LOGIN  |  REGISTER
Chimerix

Centene To Present At Bank Of America 2024 Global Healthcare Conference

September 11, 2024 | Last Trade: US$33.19 0.04 0.12

ST. LOUIS, Sept. 11, 2024 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today it will present at the Bank of America 2024 Global Healthcare Conference in London. Centene will present on Wednesday, Sept. 18, 2024, at 5:50 am EDT /10:50 am BST. A simultaneous live audio webcast will be available at: https://bofa.veracast.com/webcasts/bofa/globalhealthcareuk2024/x1aRN0.cfm.

A webcast replay will be available following the presentation on Centene's website, www.centene.com, under the Investors section.

About Centene Corporation

Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program.

Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, https://investors.centene.com/.

Stock Quote

Last Trade: US$33.19
Daily Change: 0.04 0.12
Daily Volume: 13,793,651
Market Cap: US$16.300B

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page